Ferghana Partners Group [New York, Boston, London], the international provider of high level, independent corporate finance advice to firms in the Biotechnology, Pharmaceuti- cals, Diagnostics and Specialty Chemicals industries, is pleased to announce that Michael J. Nowak has recently joined its teams as Director to focus heavily on Financing activities [private placement and PIPEs]. Michael brings over twenty years of experience in both early and late stage financing of innovative high science and technology compa- nies. He has led over three dozen financings in public Life Sciences companies listed on over ten stock exchanges around the world during the last four years for a large US- based hedge fund.
“We welcome Michael’s experience, creativity and Financing expertise,” said Bill Kridel, Managing Director and Founder of Ferghana Partners.
Prior to this appointment, Michael was a General Partner at TVM Capital, a billion dollar Euro-US venture capital fund. He also has entrepreneurial, business development and investment experience from work as a co-founder of the Xerox Venture Lab at the Xerox Palo Alto Research Center (PARC), as a VP Business Development for the emerging high tech consulting practice at McKinsey & Co., and as a Program Manager of two $100M+ investment programs at the Advanced Technology Program at the National Institute of Standards and Technology (NIST), US Department of Commerce.
Michael earned an MBA from the Wharton School at the University of Pennsylvania in Finance and Strategic Management and a PhD in Physics from the University of Califor- nia, Santa Barbara. He worked as a post-doctoral scientist at Bell Labs (Bellcore), Princeton University, and at the CEA research labs in Saclay, France. He received his BA in Physics from Cornell University in Ithaca, NY, where he was a College Scholar.
